Features and News

McCall’s Call: A First-Half Checkup

The first half’s laggards—financial ETFs—could turn out to be a second-half surprise.

Features and News

How To Play Biotech With ETFs

Biotech is looking interesting again; here’s how to play it.

Features and News

McCall’s Call: The Cancer-Cure Biotech ETFs

If you’re looking to profit from the growing array of sophisticated cancer treatments, look no further than biotech ETFs. But the devil’s in the details, as the five choices available to investors make clear.

Features and News

Investing In Obama With ETFs

moves markets with its policy initiatives. Here’s how to be on the right side of the Obama trade.

Features and News

Trio Of Alternative ETFs Remains Above The Fray

Three funds are outperforming the broader stock market. And these ETFs appear to have strong fundamentals as longer-term portfolio plays. 

Features and News

Mazzilli: Relief In Sight For Stock ETF Investors

The veteran ETF analyst says large-caps are in the best shape he's seen in more than a year. Here are his favorite U.S. & foreign funds. 

Features and News

PowerShares Goes Global In Transportation, Biotech

While not first in either sector, the new ETFs offer portfolios with U.S. as well as international exposures to stocks.

ETF Report

 streetTRACKS become SPDRs, and launch new ETFs

Like Vanguard before it, which rebranded its Vipers as ETF Share Classes last year, State Street Global Advisors dropped the streetTRACKS nomenclature in favor of the simpler and more recognizable SPDRs insignia.